Setting Standards for Care
The CRCCI is a national coalition of patient advocates, physicians, public health champions and healthcare leaders uniting around data-driven goals to transform colorectal cancer (CRC) screening, diagnosis, and treatment. Learn how your organization can join the initiative and advance our shared mission.
CRCCI Overview: Purpose, partner network, and data origin (claims data)
The CRCCI is a response to a critical gap in colorectal cancer care. We are not effectively measuring the quality of care received in the U.S. Real-world patient data provides incredible insights, but when it is not effectively utilized to inform healthcare decisions, disparities in care and outcomes persist. This leads to suboptimal screening strategies, delayed diagnoses, and inconsistent treatment approaches, particularly for younger demographics who are increasingly at risk.
The initiative leveraged peer-reviewed data, patient insights and real-world data from over 8 billion claims and over 46 million patients to establish clear, actionable goals for CRC screening and care that stakeholders across the colorectal cancer community can rally around. It serves as a tool to help healthcare systems nationwide leverage data to measure progress, allocate resources, and improve outcomes.
By becoming a member of the CRCCI, it is an endorsement of the goals and a public commitment to improving colorectal cancer care and outcomes within your community. By adopting these goals, health systems can:
- Enhance patient outcomes through early detection and timely treatment.
- Demonstrate leadership in addressing one of the nation’s most pressing public health challenges.
- Access resources, training, and tools to support successful implementation.
- Join a national network of over 40 organizations including leading patient advocacy organizations, physician organizations and industry leaders committed to saving lives through improved colorectal cancer care.
CRCCI Goals
Goal 1: Timely Screening
- Achieve an 80% screening rate for average-risk patients.
- Ensure 80% of patients with an abnormal non-invasive screening test receive a follow-up colonoscopy within 90 days (3 months).
Goal 2: Accurate, Informative Diagnosis and Timely Treatment Initiation
- Ensure 80% of patients diagnosed with CRC receive biomarker testing in accordance with NCCN Clinical Practice Guidelines (NCCN Guidelines®).
- Ensure 80% of patients diagnosed with CRC undergo germline genetic testing at the time of diagnosis.
- Ensure 80% of patients initiate treatment within six weeks of a CRC diagnosis.
Join the CRCCI Initiative
CRCCI Partners
